NCT01298323 - Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

February 25, 2011

Primary Completion Date

April 26, 2013

Study Completion Date

March 13, 2025

Conditions

Locally Advanced or Metastatic Medullary Thyroid CancerMedullary Thyroid Cancer

Interventions

BEHAVIORAL

Patient outreach

Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner

DRUG

Vandetanib

Treatment 300mg vandetanib opel label.

Trial Locations (66)

1000

Investigational Site Number 501, Brussels

1070

Investigational Site Number : 501, Anderlecht

1527

Investigational Site Number 901, Sofia

Investigational Site Number : 901, Sofia

1901

Investigational Site Number 401, Vienna

Investigational Site Number : 401, Vienna

2065

Investigational Site Number : 301, St Leonards

Investigational Site Number 301, St Leonards

5000

Investigational Site Number 2001, Odense C

Investigational Site Number : 2001, Odense C

11528

Investigational Site Number 3001, Athens

Investigational Site Number : 3001, Athens

15006

Investigational Site Number 1901, Prague

Investigational Site Number : 1901, Prague

45122

Investigational Site Number 2602, Essen

Investigational Site Number : 2602, Essen

56124

Investigational Site Number 4101, Pisa

Investigational Site Number : 4101, Pisa

75185

Investigational Site Number 7201, Uppsala

Investigational Site Number : 7201, Uppsala

91120

Investigational Site Number 4001, Jerusalem

Investigational Site Number : 4001, Jerusalem

97080

Investigational Site Number 2601, Würzburg

Investigational Site Number : 2601, Würzburg

100021

Investigational Site Number 1301, Beijing

Investigational Site Number : 1301, Beijing

115478

Investigational Site Number 6201, Moscow

Investigational Site Number : 6201, Moscow

125284

Investigational Site Number 6204, Moscow

197022

Investigational Site Number 6203, Saint Petersburg

249036

Investigational Site Number 6202, Obninsk

Investigational Site Number : 6202, Obninsk

400012

Investigational Site Number 3501, Mumbai

Investigational Site Number : 3501, Mumbai

632004

Investigational Site Number 3502, Vellore

Investigational Site Number : 3502, Vellore

90035-003

Hospital De Clinicas De Porto Alegre Site Number : 701, Porto Alegre

Investigational Site Number 701, Porto Alegre

14048-900

Faculdade de Medicina de Ribeirao Preto - USP Site Number : 702, Ribeirão Preto

Investigational Site Number 702, Ribeirão Preto

N6A 4L6

Investigational Site Number : 1001, London

Investigational Site Number 1001, London

M5G2M9

Investigational Site Number : 1003, Toronto

Investigational Site Number 1003, Toronto

J1H 5N4

Investigational Site Number : 1002, Sherbrooke

Investigational Site Number 1002, Sherbrooke

Unknown

Investigational Site Number 1302, Shanghai

Investigational Site Number : 1302, Shanghai

Investigational Site Number 4104, Napoli

Investigational Site Number : 4104, Napoli

Investigational Site Number 6001, Seoul

FI-00029

Investigational Site Number 2201, Helsinki

Investigational Site Number : 2201, Helsinki

06120

Investigational Site Number 2603, Halle

Investigational Site Number : 2603, Halle

00161

Investigational Site Number 4102, Roma

Investigational Site Number : 4102, Roma

60-355

Investigational Site Number : 5702, Poznan

Investigational Site Number 5702, Poznan

02-781

Investigational Site Number : 5703, Warsaw

Investigational Site Number 5703, Warsaw

03080

Investigational Site Number : 6001, Seoul

SM25PT

Investigational Site Number : 2801, Sutton

Investigational Site Number 2801, Sutton

G120YN

Investigational Site Number 2802, Glasgow

Investigational Site Number : 2802, Glasgow